Cargando…
Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy
Background: The piracetam analog, aniracetam, has recently received attention for its cognition enhancing potential, with minimal reported side effects. Previous studies report the drug to be effective in both human and non-human models with pre-existing cognitive dysfunction, but few studies have...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998011/ https://www.ncbi.nlm.nih.gov/pubmed/29946420 http://dx.doi.org/10.12688/f1000research.11023.3 |
_version_ | 1783331165711630336 |
---|---|
author | Reynolds, Conner D. Jefferson, Taylor S. Volquardsen, Meagan Pandian, Ashvini Smith, Gregory D. Holley, Andrew J. Lugo, Joaquin N. |
author_facet | Reynolds, Conner D. Jefferson, Taylor S. Volquardsen, Meagan Pandian, Ashvini Smith, Gregory D. Holley, Andrew J. Lugo, Joaquin N. |
author_sort | Reynolds, Conner D. |
collection | PubMed |
description | Background: The piracetam analog, aniracetam, has recently received attention for its cognition enhancing potential, with minimal reported side effects. Previous studies report the drug to be effective in both human and non-human models with pre-existing cognitive dysfunction, but few studies have evaluated its efficacy in healthy subjects. A previous study performed in our laboratory found no cognitive enhancing effects of oral aniracetam administration 1-hour prior to behavioral testing in naïve C57BL/6J mice. Methods: The current study aims to further evaluate this drug by administration of aniracetam 30 minutes prior to testing in order to optimize any cognitive enhancing effects. In this study, all naïve C57BL/6J mice were tested in tasks of delayed fear conditioning, novel object recognition, rotarod, open field, elevated plus maze, and marble burying. Results: Across all tasks, animals in the treatment group failed to show enhanced learning when compared to controls. Conclusions: These results provide further evidence suggesting that aniracetam conveys no therapeutic benefit to subjects without pre-existing cognitive dysfunction. |
format | Online Article Text |
id | pubmed-5998011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-59980112018-06-25 Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy Reynolds, Conner D. Jefferson, Taylor S. Volquardsen, Meagan Pandian, Ashvini Smith, Gregory D. Holley, Andrew J. Lugo, Joaquin N. F1000Res Research Article Background: The piracetam analog, aniracetam, has recently received attention for its cognition enhancing potential, with minimal reported side effects. Previous studies report the drug to be effective in both human and non-human models with pre-existing cognitive dysfunction, but few studies have evaluated its efficacy in healthy subjects. A previous study performed in our laboratory found no cognitive enhancing effects of oral aniracetam administration 1-hour prior to behavioral testing in naïve C57BL/6J mice. Methods: The current study aims to further evaluate this drug by administration of aniracetam 30 minutes prior to testing in order to optimize any cognitive enhancing effects. In this study, all naïve C57BL/6J mice were tested in tasks of delayed fear conditioning, novel object recognition, rotarod, open field, elevated plus maze, and marble burying. Results: Across all tasks, animals in the treatment group failed to show enhanced learning when compared to controls. Conclusions: These results provide further evidence suggesting that aniracetam conveys no therapeutic benefit to subjects without pre-existing cognitive dysfunction. F1000 Research Limited 2018-06-22 /pmc/articles/PMC5998011/ /pubmed/29946420 http://dx.doi.org/10.12688/f1000research.11023.3 Text en Copyright: © 2018 Reynolds CD et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Reynolds, Conner D. Jefferson, Taylor S. Volquardsen, Meagan Pandian, Ashvini Smith, Gregory D. Holley, Andrew J. Lugo, Joaquin N. Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy |
title | Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy |
title_full | Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy |
title_fullStr | Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy |
title_full_unstemmed | Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy |
title_short | Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy |
title_sort | oral aniracetam treatment in c57bl/6j mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998011/ https://www.ncbi.nlm.nih.gov/pubmed/29946420 http://dx.doi.org/10.12688/f1000research.11023.3 |
work_keys_str_mv | AT reynoldsconnerd oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy AT jeffersontaylors oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy AT volquardsenmeagan oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy AT pandianashvini oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy AT smithgregoryd oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy AT holleyandrewj oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy AT lugojoaquinn oralaniracetamtreatmentinc57bl6jmicewithoutpreexistingcognitivedysfunctionrevealsnochangesinlearningmemoryanxietyorstereotypy |